Zdrowie i gospodarka · 20/10/1997

FDA Amends Notice of Cardiovascular and Renal Drugs Advisory Committee Meeting

The FDA is updating the agenda for the Cardiovascular and Renal Drugs Advisory Committee meeting, removing a previously scheduled item and adding a closed session, with the changes to take effect on October 23, 1997.